Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Tuesday. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

Organovo stock opened at $0.43 on Tuesday. The stock’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.45. The firm has a market capitalization of $7.35 million, a PE ratio of -0.50 and a beta of 0.45. Organovo has a one year low of $0.32 and a one year high of $1.83.

Organovo (NASDAQ:ONVO) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. On average, analysts forecast that Organovo will post -0.77 earnings per share for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.